Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:focusArea |
gptkb:cancer
immunology inflammatory disorders |
| gptkbp:foundedBy |
gptkb:Robert_J._Hugin
gptkb:Sol_J._Barer gptkb:David_Stirling gptkb:John_W._Jackson |
| gptkbp:foundedIn |
1986
|
| gptkbp:headquartersLocation |
gptkb:Summit,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celgene Corporation
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:keyPerson |
gptkb:Mark_J._Alles
|
| gptkbp:netIncome |
$4.0 billion (2018)
|
| gptkbp:notableInvention |
gptkb:thalidomide
gptkb:lenalidomide |
| gptkbp:numberOfEmployees |
~7,500 (2018)
|
| gptkbp:parentCompany |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:product |
gptkb:Pomalyst
gptkb:Revlimid gptkb:Abraxane |
| gptkbp:revenue |
$13.0 billion (2018)
|
| gptkbp:status |
defunct (as of 2019)
|
| gptkbp:stockSymbol |
gptkb:CELG
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.celgene.com
|
| gptkbp:bfsParent |
gptkb:CELG
|
| gptkbp:bfsLayer |
7
|